The Zug-based Quercis Pharma AG has licensed two key patents for its thromboembolism platform. According to a press release, the company has entered into an exclusive and worldwide agreement with the Beth Israel Deaconess Medical Center in Boston, a teaching hospital affiliated with Harvard Medical School.
The patents cover the inhibition of soluble P-selectin. This firstly helps to prevent or reduce thrombotic events in cancer patients and secondly relates to the transport of cancerous cells in the blood stream, which is the process that leads to tumors metastasizing.
“Gaining the exclusive license to these patents is important to Quercis, not only because it expands the patent estate for our lead drug candidate from 2031 to 2039 in venous thromboembolism (VTE), but also as it relates to the role P-selectin plays in the cascade of events that leads to Acute Respiratory Disease Syndrome (ARDS) in COVID-19 patients”, explains Dr. Stefan Wohlfeil, Chief Medical Officer of Quercis Pharma.
As Quercis also explains in the press release, the company is working with a series of global healthcare providers to accelerate Phase II/III clinical trials to confirm the ARDS hypothesis. These studies are ultimately aimed at offering effective prophylactic and treatment options to COVID-19 patients.
Related news
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com